YMAB: Y-mAbs Therapeutics Inc Kompaniya qiymatining sof foydaga nisbati
Y-mAbs Therapeutics (YMAB) o'z hamkorlarining avtomatlashtirilgan imkoniyatlaridan foydalangan holda, molekulalarni loyihalash uchun sun'iy intellektni joriy qilmoqda. Kompaniya RSU tizimi va ishga bo'lgan etik yondashuv orqali yetakchi antitanalar mutaxassislarini jalb qilmoqda. -18.10 darajasidagi bozor baholash tendentsiyasi DANYELZA ning o'sish potentsialini va bolalar o'smalari uchun aniq terapiya sohasidagi samarali R&D pipeline holatini tasdiqlaydi.
%20P%2FE%20multiplikatori&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_YMAB_-_Y-mAbs-Therapeutics_-_PE-Multiple "YMAB: ymabs.com Narx-foyda koeffitsiyenti 04.07.2022 - 27.09.2025 | 👁️GURU.Markets👁️")
YmAbs (YMAB) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- aksiya kursi va ekspertlarning narx prognozi:
- bozor kapitallashuvi haqida ma'lumot:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Barcha qarzlarning o‘z mablag‘lariga nisbati Y-mAbs Therapeutics|YMAB - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati Y-mAbs Corp|YMAB - Kompaniyaning umumiy qarzi|Balans qiymatiga qarzlar Y-mAbs Therapeutics, Inc.|YMAB - Kompaniyaning uzoq muddatli majburiyatlari|Qisqa muddatli qarzdorlik Y-mAbs Therapeutics|Tezkor likvidlik ko‘rsatkichi ymabs.com
- kompaniyaning daromadliligi va baholash multiplikatorlari ko'rsatkichlari:
YMAB - Sof foyda|Prognoz qilingan kelajakdagi foyda Y-mAbs Therapeutics|YMAB - P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Y-mAbs Therapeutics Inc|YMAB - Narxning foydaga va o‘sish sur’atiga nisbati|Kompaniyaning to‘liq qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Y-mAbs Therapeutics, Inc.|YMAB - Eskirish chegirilmasdan oldingi operatsion foyda|Sirpanuvchi yil uchun bir aksiya uchun foyda Y-mAbs Therapeutics|YMAB - So'nggi 12 oy davomida bir aksiya uchun sof foyda|So'nggi o'n ikki oy davomida bir aksiya uchun foydaning yillik o'sish sur'ati ymabs.com|YMAB - Joriy yilda foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning kutilayotgan dinamikasi Y-mAbs Therapeutics
Kompaniyaning umumiy tahlili:YMAB (ymabs.com)
Y-mAbs Therapeutics (YMAB) Danyelza ni tijoratlashtirish orqali pediatrik onkologiya segmentida ustunlikka intilmoqda. Kompaniyaning P/E grafigini tahlil qilib, investor aktivning bozor qiymatining uning sof foydasiga nisbatini ko'radi. Ushbu ko'rsatkich har bir topilgan kapital dollarining xarajatini o'lchash orqali nazariy qoplash muddatini belgilaydi. Biroq, distribyutsiya tarmog'ini kengaytirish jarayonida qarz o'sishini e'tiborsiz qoldirish kapitalning illikvid aktivda muzlab qolish xavfini tug'dirishi mumkin.
Raqobatdosh kompaniyalar
ONC: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti HALO (Halozyme)|RVMD (Revolution Medicines Inc) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori AAPG (Ascentage)|CGON - Narx-foyda koeffitsiyenti|URGN: Narx-foyda koeffitsiyenti|BCAX - P/E multiplikatori|Personalis (PSNL) - Narxning foydaga nisbati|Erasca Inc - Kompaniya qiymatining sof foydaga nisbati|DCTH (Delcath) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Aura Corp AURA|Narx-foyda koeffitsiyenti CADL (Candel Therapeutics)|ARAY - Kapitalizatsiyaning foydaga nisbati|SELLAS Life Sciences Group - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Actuate Therapeutics Inc.|CTOR - Narxning foydaga nisbati|TuHURA Biosciences, Inc. (HURA) - Narx-foyda koeffitsiyenti|TARA: P/E multiplikatori|fatetherapeutics.com (FATE) - P/E multiplikatori|WHWK (Aadi Bioscience, Inc.) - P/E multiplikatori|Narxning foydaga nisbati TCRX|Narxning foydaga nisbati Champions Oncology (CSBR)|Biznesning o‘zini qoplash muddati xbiotech.com|CEL-SCI - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati OSTX|RADX: Narx-foyda koeffitsiyenti|Artiva Biotherapeutics, Inc. - Bozor narxining sof foydaga nisbati|ANL: P/E multiplikatori|Veru Corporation - Kompaniya qiymatining sof foydaga nisbati|TPST (Tempest Therapeutics) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Xilio XLO|Narxning foydaga nisbati Renovaro Inc. (RENB)|MURA (muraloncology.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori KAPA (Kairos Pharma)|P/E multiplikatori OnKure Therapeutics, Inc. OKUR|GDTC - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati CRIS|APLM: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Tharimmune Inc (THAR)|Narx-foyda koeffitsiyenti ADVB|P/E multiplikatori Genprex Inc|Narx-foyda koeffitsiyenti CLDI (Calidi Biotherapeutics)|Bozor narxining sof foydaga nisbati SBFM|P/E multiplikatori XBIO (Xenetic Biosciences, Inc.)|Biznesning o‘zini qoplash muddati Salarius Pharmaceuticals Inc (SLRX)|Purple Biotech Corp - P/E multiplikatori|American Oncology Network (AONC) - Narx-foyda koeffitsiyenti|BeiGene, Ltd. (BGNE) - Narxning foydaga nisbati|CKPT - Biznesning o‘zini qoplash muddati|Narx-foyda koeffitsiyenti ELEV|Kapitalizatsiyaning foydaga nisbati iCAD Corp ICAD|Narxning foydaga nisbati Ikena Oncology, Inc. (IKNA)|Narx-foyda koeffitsiyenti Notable Labs Corp NTBL|P/E multiplikatori VIRX (Viracta Therapeutics, Inc.)|P/E multiplikatori morphosys.com MOR|NAYA Biosciences Inc. - P/E multiplikatori|AAPGV: Narxning foydaga nisbati
